Dan O'Day, Gilead CEO (Andrew Harnik/AP Images)
Gilead calls dibs on a PhI bispecific, hands over $60M to cash-strapped MacroGenics
On a continual search for more baskets to put its oncology eggs in, Gilead has landed on a hot target: CD123.
Specifically, Gilead is grabbing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
